RxDoctor Payments Data

Shama Quraishi, MD

Family Medicine · Beaumont, TXNPI 1649262007

Payments from drug & device makers

$1,071in general payments, 2019–2025

Across 47 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$284
  • AbbVie$233
  • GSK$209
  • Pfizer$64
  • Sunovion Pharmaceuticals Inc.$57
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$42
  • plus $181 from 10 others

What the payments were for

  • Food & beverage$1,071100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,071 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$77,253
Medicare patients
157
Services billed
1,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$64,994
OzempicSemaglutide57$64,227
JanuviaSitagliptin Phosphate63$56,877
JardianceEmpagliflozin21$30,779
MyrbetriqMirabegron31$30,482
Tresiba Flextouch U-200Insulin Degludec27$27,217
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,173
MounjaroTirzepatide11$11,340
Albuterol Sulfate HfaAlbuterol Sulfate200$10,829
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen331$9,474
Combivent RespimatIpratropium/Albuterol Sulfate13$7,767
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$4,828
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$4,535
Gabapentin277$4,521
VascepaIcosapent Ethyl12$4,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$64,99468 claims
Novo NordiskOzempic$11$64,22757 claims
MerckJanuvia$17$56,87763 claims
GSKTrelegy Ellipta$209$16,17316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →